1. Litlhaku: Phofo e tšoeu kapa e batlang e le tšoeu, e nang le hygroscopic haholo.
2. Mohloli: Mucosa ea mala a kolobe.
3. Ts'ebetso: Sodium ea Heparin e ntšoa ho tswa ho porcine intestine mucosa e phetseng hantle.
4. Lipontšo le tšebeliso: Sehlahisoa sena se sebelisoa haholo-holo bakeng sa thibelo ea lefu la thromboembolic, haholo-holo e loketseng tlhokahalo ea anticoagulant ka potlako, e kang: 1. Acute or chronic venous thrombosis kapa ha ho na phetoho e matla ea phallo ea mali ea pulmonary embolism (PE) .Heparin e ka emisa katoloso ea embolus ho ipha nako ea thrombolysis ea 'mele e itlelang feela.2. Thibelo le kalafo ea Atrial fibrillation ka embolism.3. Kalafo ea pele ea diffuse intravascular coagulation(DIC).4. Thibelo le kalafo ea peripheral arterial thrombosis kapa myocardial infarction.5. Anticoagulation e 'ngoe ea in vitro: joalo ka opereishene ea pelo, potoloho ea mali, hemodialysis, angiography, le eona e ka sebelisoa bakeng sa tšelo ea mali kapa tokiso ea mohlala oa mali, hajoale matšoao a mantlha a tšebeliso ea heparin ke deep vein thrombosis(DVT), PE le thrombosis. ho bakuli ba kotsing e kholo.
· E fetisitse Chinese GMP
· Lilemo tse 27 tsa nalane ea enzyme ea bioloji ea R&D
· Lisebelisuoa tse tala lia lateloa
·Latela USP,EPle maemo a bareki
· Romella kantle ho naha le libakeng tse fetang 30
·E na le bokhoni ba tsamaiso ea boleng bo kang US FDA, Japan PMDA, South Korea MFDS, joalo-joalo.
Lintho tsa Tlhahlobo | Tlhaloso ea Khampani | ||
EP | USP | ||
Litlhaku | Phofo e tšoeu kapa e batlang e le tšoeu, e nang le hygroscopic haholo | ||
Boitsebiso | Thrombotest: E lumellana | Boitsebiso ba Chromatographic: Bo lumellana | |
1H NMR Spectrum: E lumellana | 1H NMR Spectrum: E lumellana | ||
Liquid Chromatography: E lumellana | Boima ba boima ba 'mele: 15000 ~ 19000 | ||
Sodium: E lumellana | Sodium: E lumellana | ||
Anti-factor Xa to anti-factor IIa ratio:0.9 ~ 1.1 | Anti-factor Xa to anti-factor IIa ratio:0.9 ~ 1.1 | ||
Liteko | Ho hlaka le mmala | Ho hlaka: Ho hlakile, Mmala: ka 5 kapa ho feta | ———— |
Naetrojene | 1.5~2.5%(ntho e ommeng) | 1.3~2.5%(ntho e ommeng) | |
Litšila tsa Nucleotidic | A260≤ 0.15(4mg/ml) | ≤ 0.1(w/w) | |
Lintho tse amanang | E lumellana | ———— | |
Moeli oa galactosamine ka kakaretso ea hexosamine | ———— | ≤ 1.0% | |
Oversulfate chondroitin sulfate | ———— | E lumellana | |
pH | 5.5~8.0(1%) | 5.5~7.5(1%) | |
Tahlehelo ka ho omisa | ≤ 8.0%(60 ℃ Omisa ka Vacuum, 3h) | ≤ 5.0%(60 ℃ Omisa ka Vacuum, 3h) | |
Masalla ha a tuka | ———— | 28.0%~41.0% | |
Endotoxin ea baktheria | ≤ 0.01 IU/Setsi sa Machaba sa Heparin | ≤ 0.03 USP U / International Unit ea Heparin | |
Tšepe e boima | ≤ 30ppm | ≤ 30ppm | |
Sodium | 10.5~13.5%(ntho e ommeng) | ———— | |
Liprotheine | ≤ 0.5%(ntho e ommeng) | ≤ 0.1%(Karolelano ea boima ba 'mele) | |
Ketsahalo | ≥ 180 IU/mg(ntho e ommeng) | ≥ 180 USP U/mg(ntho e ommeng) | |
Litšila tsa Microbial | TAMC | ≤ 1000cfu/g | ≤ 1000cfu/g |
TYMC | ≤ 100cfu/g | ≤ 100cfu/g | |
E.coli | E lumellana | E lumellana | |
Staphylococcus aureus | E lumellana | E lumellana | |
Salmonella | E lumellana | E lumellana |